Perspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 52-Week High at $1.90

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high on Wednesday . The company traded as high as 1.90 and last traded at 1.84, with a volume of 3917500 shares changing hands. The stock had previously closed at 1.83.

Analysts Set New Price Targets

A number of research firms recently issued reports on CATX. Oppenheimer reaffirmed an “outperform” rating and set a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley increased their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a report on Tuesday, April 9th.

Perspective Therapeutics Trading Up 0.5 %

The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -18.40 and a beta of 1.43. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently made changes to their positions in CATX. RIA Advisory Group LLC boosted its holdings in shares of Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the period. ZWJ Investment Counsel Inc. bought a new position in shares of Perspective Therapeutics during the 1st quarter worth $26,000. Simplicity Wealth LLC purchased a new position in shares of Perspective Therapeutics during the first quarter valued at $40,000. Taylor & Morgan Wealth Management LLC raised its holdings in shares of Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Perspective Therapeutics in the third quarter worth about $314,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.